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Our previous work has demonstrated that the Tudor domain of the ‘survival of motor neuron’ protein and the
Tudor domain-containing protein 3 (TDRD3) are highly similar and that they both have the ability to interact
with arginine-methylated polypeptides. TDRD3 has been identiﬁed among genes whose overexpression has a
strong predictive value for poor prognosis of estrogen receptor-negative breast cancers, although its precise
function remains unknown. TDRD3 is a modular protein, and in addition to its Tudor domain, it harbors a
putative nucleic acid recognition motif and a ubiquitin-associated domain. We report here that TDRD3 loca-
lizes predominantly to the cytoplasm, where it co-sediments with the fragile X mental retardation protein on
actively translating polyribosomes. We also demonstrate that TDRD3 accumulates into stress granules (SGs)
in response to various cellular stresses. Strikingly, the Tudor domain of TDRD3 was found to be both
required and sufﬁcient for its recruitment to SGs, and the methyl-binding surface in the Tudor domain is
important for this process. Pull down experiments identiﬁed ﬁve novel TDRD3 interacting partners, most
of which are potentially methylated RNA-binding proteins. Our ﬁndings revealed that two of these proteins,
SERPINE1 mRNA-binding protein 1 and DEAD/H box-3 (a gene often deleted in Sertoli-cell-only syndrome),
are also novel constituents of cytoplasmic SGs. Taken together, we report the ﬁrst characterization of
TDRD3 and its functional interaction with at least two proteins implicated in human genetic diseases and pre-
sent evidence supporting a role for arginine methylation in the regulation of SG dynamics.
INTRODUCTION
Cell signaling pathways rely heavily on modular proteins con-
taining protein–protein interaction domains to sense, transmit
and process signals that regulate cellular functions (1). The
domains involved in these interactions recognize speciﬁc
peptide motifs in their binding partner, and this recognition
can be further inﬂuenced by the presence of post-translational
modiﬁcations, such as phosphorylation, ubiquitination or
methylation. These modiﬁcations can be either added or
removed to create dynamic changes in protein binding proper-
ties, thus enabling rapid cellular responses to both external and
internal stimuli.
Arginine methylation is a common post-translational modi-
ﬁcation that has been shown to play central roles in signal
transduction pathways regulating many cellular processes,
including cell growth, transcription and DNA repair (2–4).
Although a number of proteomic screens have now signiﬁ-
cantly expanded the repertoire of arginine-methylated proteins
(5–7), RNA-binding proteins remain a predominant class of
the proteins harboring this modiﬁcation. Consistent with this
observation, several studies have also suggested roles for argi-
nine methylation in the regulation of various post-
transcriptional processes, including pre-mRNA splicing
(8,9), mRNA export (10) and translation (11,12). However,
the precise molecular mechanisms involved in the regulation
of these processes remain largely unknown. Several lines of
evidence support the idea that arginine methylation may
serve as an important regulatory signal in these cellular path-
ways. First, methylated arginines have been shown to be
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actions (8,13–15). Second, these modiﬁed arginines are
speciﬁcally recognized by a protein module termed ‘Tudor
domain’ (16,17). Third, the recent discovery of enzymes that
can remove the methylation mark (18–20) conﬁrms that this
modiﬁcation is dynamic.
The Tudor domain is a 60-amino acid motif that was ﬁrst
discovered through a protein sequence comparison analysis,
performed to identify conserved patterns in Drosophila
Tudor (21,22), a protein involved in germ cell formation
that harbors 11 repeated Tudor domains. Tudor domains are
highly conserved throughout evolution: they can be found in
virtually all organisms, from bacteria to mammals. In the
latter, approximately 15 ‘Tudor Domain-containing proteins’
(TDRD1, 2, etc.) can be found in sequence databases; the
functions of most remaining largely unknown. The Tudor
domain of the ‘survival of motor neuron’ (SMN) protein, the
causative gene for spinal muscular atrophy, is by far the best
characterized. Three-dimensional structure determination of
the SMN Tudor fold revealed a barrel-like structure composed
of b-sheets forming a hydrophobic pocket, surrounded by
negatively charged and aromatic residues, which together
likely constitute the protein–protein interaction surface
(23,24). This structural fold shares similarities with the
Chromo domain, a motif known to interact with methylated
lysines in histones (25). This resemblance led to the prop-
osition that methyl-substrate binding might be a general
feature of these related domains. Several studies have now
indeed demonstrated methyl-dependent interactions between
the Tudor domain of SMN and a number of arginine-
methylated proteins (9,17,26–29). Other studies have also
suggested the existence of another subclass of Tudor
domains, dubbed ‘tandem Tudor’, which recognize methylated
lysines instead of arginines (16,30). These include the Tudor
domains of 53BP1 (31,32) and JMJD2A (33). Taken together,
these ﬁndings support the notion that the Tudor domain is a
bona ﬁde ‘protein module’.
Interestingly, several of the ﬁrst Tudor domain-containing
proteins that were identiﬁed also possessed RNA-binding
capacity, which led to the suggestion that Tudor domains
may play a role in RNA metabolism (22). Further evidence
supporting this hypothesis has now been provided, as
common themes are starting to emerge. First, structural analy-
sis of the N-terminal domain of fragile X mental retardation
protein (FMRP), a well-characterized KH-containing RNA-
binding protein, revealed the presence of a Tudor domain
(34). This Tudor-KH conﬁguration is also found in at least
one other protein (35). This suggests that these modular pro-
teins could serve as scaffolding proteins involved in the inte-
gration of arginine methylation signals and RNA processing.
Second, the Tudor-SN protein was shown to participate in
both RNA interference and RNA editing pathways (36).
Third, SMN promotes the transfer of core Sm proteins to
snRNAs in the cytoplasmic assembly of spliceosomal small
nuclear ribonucleoprotein particles (snRNPs) (17,37–39),
and it is thought to serve as a ‘master assembler’ of many
additional RNP complexes (40–42). Finally, SMN (8,37,43)
and two other Tudor domain-containing proteins, SPF30
(44,45) and p100 (46,47), have all been shown to play a role
in pre-mRNA splicing. These observations suggest that
Tudor domains may serve as molecular adaptors in post-
transcriptional processes regulated by arginine methylation.
The TDRD3 is a novel modular protein of unknown func-
tion. It was identiﬁed among genes whose overexpression
has a strong predictive value for poor prognosis of estrogen
receptor-negative breast cancers (48). This suggests that
TDRD3 may contribute to the progression of breast cancer.
Its Tudor domain is highly similar to that of SMN and we
have recently demonstrated that it also has the ability to
bind arginine-methylated polypeptides (17). In addition to its
Tudor domain, TDRD3 harbors a DUF/OB-fold motif (puta-
tive nucleic acid recognition motif), as well as a UBA
(ubiquitin-binding domain A) domain (49). As suggested by
the presence of both nucleic acid- and methyl-binding proper-
ties, we speculated that TDRD3 could be central in RNA pro-
cessing regulatory pathways involving arginine methylation.
In order to gain insight into its cellular function, we gener-
ated antibodies against TDRD3 and undertook its biochemical
characterization. Immunoﬂuorescence (IF) microscopy studies
showed that TDRD3 localizes diffusely in both the cytoplasm
and the nucleus. Interestingly, we observed that TDRD3 colo-
calizes with TIA-1, G3BP and FMRP in cytoplasmic stress
granules (SGs) in response to various cellular stresses. SGs
become visible at the microscopic level upon various environ-
mental stresses, but recent studies suggest they may represent
natural sites of cytoplasmic mRNA sorting/triage that play a
major role in the post-transcriptional regulation of gene
expression by regulating the localization, stability and trans-
lation of many mRNAs (50–52). Known constituents of SGs
can be catalogued within the following categories: (i) trans-
lation factors, (ii) mRNAs, (iii) mRNA-binding proteins with
roles in the regulation of translation and/or mRNA stability,
(iv) proteins linked with mRNA metabolism and (v) signaling
proteins with no known links with RNA metabolism (53).
Expression of TDRD3 deletion mutants in HeLa cells revealed
that its Tudor domain is both required and sufﬁcient for its
localization to SGs. Pull down experiments using its isolated
Tudor domain led to the identiﬁcation of ﬁve interacting pro-
teins with known functions in various aspects of RNA hand-
ling. Strikingly, we show that two of them, DEAD/H box-3
(an RNA helicase also known as DDX3X/Y, DBX/Y, HLP2
and DDX14) and SERPINE1 mRNA-binding protein 1
(SERBP1), also localize to SGs following sodium arsenite
treatment. Taken together, our results place TDRD3 in com-
plexes with at least two proteins implicated in human
genetic diseases (FMRP and DDX3) and suggest a role for
arginine methylation in the regulation of SG dynamics.
RESULTS
TDRD3 is a novel modular protein
Data obtained from the UCSC Genome Browser (human Mar.
2006 hg18 assembly; NCBI Build 36.1) revealed that the
human TDRD3 gene consists of 14 exons spanning a region
of 176.5 kb of genomic DNA on chromosome 13q21.2
(Fig. 1A). All splicing junctions conform to the GU-AG
general consensus and the resulting mRNA is 2.9 kb in
length (Fig. 1B). The TDRD3 mRNA sequence found in
databases (GenBank accession no. NM_030794) contains 10
3056 Human Molecular Genetics, 2008, Vol. 17, No. 19Figure 1. Genomic organization of the human TDRD3 locus and schematic representation of the TDRD3 protein. Analysis of the human TDRD3 gene locus
revealed 14 exons spanning over 176.5 kb of genomic DNA, encoding a 2.9-kb mRNA transcript (A). The sequence of exons is displayed with capital letters
above the amino acid sequences they encode. Only short sequences around the intron boundaries are shown with small letters. All of the exon-intron junctions
(shown in black boxes) conform to the GU-AG general consensus. The start and stop codons are in bold, whereas the Kozak sequence and the polyadenylation
signal are underlined. Both nucleotides and amino acids are numbered starting from the ATG codon (B). The encoded TDRD3 protein consists of 744 amino
acids arranged in a modular fashion. Data obtained from the NCBI Conserved Domains and the Protein Family (Pfam version 22.0) databases predict the pre-
sence of three structural domains in TDRD3: a DUF1767/OB-fold (amino acids 13–169), a UBA (amino acids 286–328) and a Tudor (amino acids 651–710)
domain (see text for details) (C).
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codon (here designated as M94) located within exon 4. The
TDRD3 transcript derived from our analysis of the human
genomic sequence (GenBank accession no. EU643838), with
reference to reported cDNAs and expressed sequence tags,
unveiled an additional upstream in-frame initiation codon
within the ﬁrst exon. The sequence preceding this new ATG
(M1) is a better match to the Kozak consensus sequence
(54) than the previously proposed initiation codon (Fig. 1B).
This extended TDRD3 coding sequence therefore contains
three additional coding exons (1–3) upstream of the pre-
viously described exons 4–13. The STOP codon (TAA) falls
within exon 13 and the polyadenylation signal (AATAAA)
is located in the non-coding exon 14 (Fig. 1A and B). The pre-
sence of these upstream exons in the mRNA coding sequence
was conﬁrmed by RT–PCR and subsequent sequencing using
total RNA from HeLa cells.
The predicted TDRD3 protein consists of 744 amino acids
and has a calculated molecular weight of 82.7 kDa
(GenBank accession no. ACC94142). Amino acid sequence
similarity analysis provided by the NCBI Conserved
Domains and the Protein Family (Pfam version 22.0) data-
bases suggests that TDRD3 is a modular protein (Fig. 1C).
In addition to its Tudor domain (amino acids 647–710),
which selectively recognizes arginine-methylated motifs in
proteins (17), TDRD3 also contains an UBA domain (amino
acids 286–328), a motif found in several proteins having con-
nections to ubiquitin and the ubiquitination pathway (49).
Moreover, while searching for proteins sharing homologies
with the Bloom’s syndrome-associated polypeptide 75
(BLAP75) protein, Yin and colleagues identiﬁed a putative
OB-fold in the N-terminal region of TDRD3 (amino acids
94–169) (55). OB-folds are compact structural motifs
usually formed of ﬁve b-sheets that are often used for
nucleic acid recognition, although they have also been
observed at protein–protein interfaces (56). This search,
however, was limited to the ‘truncated’ TDRD3 sequence
available in databases. A new search within the Pfam database
using full-length TDRD3 amino acid sequence revealed that
its OB-fold is associated with another putative motif, the
DUF1767 domain (amino acids 13–95). This eukaryotic
domain has no known function, but is often found at the
N-terminus of a nucleic acid-binding motif (Pfam number
PF08585). The modular domain structure of TDRD3 suggests
that it may serve as an adaptor molecule for various signaling
pathways.
TDRD3 intracellular distribution
In order to characterize the TDRD3 protein, a rabbit polyclonal
antibody was raised against a synthetic peptide [coupled to
keyhole limpet hemocyanine (KLH)] corresponding to the last
22 C-terminal amino acids of TDRD3 (
723DGQPRRSTRP
TQQFYQPPRARN
744). The afﬁnity-puriﬁed antibody recog-
nized a single band of 83 kDa on immunoblots (IB) per-
formed using HeLa cell extracts (Fig. 2A, lane 1), which
corresponds to the predicted molecular weight of TDRD3.
Immunoreactivity to endogenous TDRD3 in western blots
was completely abolished by preincubation of TDRD3 anti-
bodies with the antigenic peptide, but not with an unrelated
peptide, demonstrating the speciﬁcity of our antibody
(Fig. 2A, compare lanes 2 with 3). To further conﬁrm that
our antibodies speciﬁcally recognize the TDRD3 protein, in
vitro coupled transcription/translation (IVTT) reactions were
programmed with a construct designed to produce a
hexahistidine-tagged truncated version of TDRD3 (DN328 in
Fig. 5A), which still contains the reactive epitope. This
TDRD3 C-terminal domain was effectively recognized by our
TDRD3 antiserum in western blot analysis of the programmed
IVTT reactions but not in control reactions (Fig. 2B, compare
lanes 2 with 1), conﬁrming that our antibody recognizes the
TDRD3 protein sequence. Interestingly, the antibody also
speciﬁcally recognized a single band corresponding to
TDRD3 predicted molecular weight in the rabbit reticulocyte
lysates, suggesting that TDRD3 is found endogenously in
these lysates (Fig. 2B, lanes 1 and 2).
We next performed indirect IF microscopy with our poly-
clonal antibody in HeLa cells to examine the subcellular dis-
tribution of endogenous TDRD3. In most cells, TDRD3
staining was detected as being predominantly cytoplasmic
and weakly nuclear diffused. In the cytoplasm, the ﬂuorescent
signal was generally more intense in the perinuclear region,
while gradually decreasing towards the edge of the cytoplasm
(Fig. 2Ca), a staining pattern reminiscent of proteins associ-
ated with polyribosomes and/or the endoplasmic reticulum.
Again, preincubation of the afﬁnity-puriﬁed antibody with
an increasing amount of the immunogenic peptide resulted
in a gradual decrease in the intensity of the IF signal, demon-
strating the speciﬁcity of the observed staining pattern
(Fig. 2Cb–e).
In order to conﬁrm the observed TDRD3 subcellular distri-
bution, we fractionated HeLa cells using the Qproteome
Nuclear Protein Kit (Qiagen). Total proteins from each frac-
tion were resolved by SDS–PAGE and immunoblotted with
our TDRD3 antibodies, as well as with nuclear (ewing
sarcoma, EWS) and cytoplasmic (GAPDH) marker antibodies
to assess the efﬁciency of our fractionation (Fig. 2D, top).
Relative abundance of TDRD3 in each fraction was deter-
mined by quantiﬁcation of band intensity using the ImageJ
version 1.37 software and expressed as a percentage of the
total signal intensity obtained from all of the fractions.
Although detectable in the nuclear and nuclear insoluble frac-
tions (37%), TDRD3 was found predominantly associated
with the cytosolic fraction (63%) (Fig. 2D, bottom), which
correlated well with the subcellular distribution observed by
IF. Taken together, these observations suggest that TDRD3
is found predominantly in the cytoplasmic compartment.
TDRD3 is a novel component of cytoplasmic SGs
In an attempt to identify in which cellular structures TDRD3
speciﬁcally localizes to in the cytoplasm, we transfected
HeLa cells with commercially available pECFP vectors encod-
ing the enhanced cyan ﬂuorescent protein fused to either
an endoplasmic reticulum (pECFP-ER), a Golgi apparatus
(pECFP-Golgi) or a mitochondrial targeting sequence
(pECFP-Mito). The cells were ﬁxed and indirect IF staining
was performed using TDRD3 antibodies. Surprisingly,
TDRD3 was found concentrated in cytoplasmic granule-like
foci in most transfected cells (data not shown), which led us
3058 Human Molecular Genetics, 2008, Vol. 17, No. 19Figure 2. A polyclonal antibody against the novel TDRD3 protein. A HeLa total cell extract was immnublotted using our afﬁnity-puriﬁed anti-TDRD3 poly-
clonal antibody (lane 1). Alternatively, immunoblots were performed using the TDRD3 antibody preincubated with a 200-fold molar excess of either the anti-
genic peptide (lane 2) or an unrelated peptide (ctrl; lane 3) (A). In vitro transcription and translation reactions were programmed to express a
hexahistidine-tagged truncated version of TDRD3 (DN328). Control (2) and programmed (þ) reactions were resolved by SDS–PAGE, transferred to a
PVDF membrane, and immunoblotted with either TDRD3 (lanes 1 and 2) or His (lanes 3 and 4) antibodies (B). Actively growing HeLa cells were labeled
for immunoﬂuorescence with our TDRD3 antibody (a). Alternatively, TDRD3 antibodies were preincubated with an increasing amount (2.5–25 g) of the immu-
nogenic peptide for 1 h on ice prior to immunoﬂuorescence staining (b–e) (C). HeLa cells were fractionated using the Qproteome Nuclear Protein Kit (Qiagen).
2.5% of each fraction was resolved by SDS–PAGE, transferred to PVDF and immunoblotted with afﬁnity-puriﬁed anti-TDRD3. Cellular fractionation efﬁciency
was assessed using antibodies against the nuclear protein EWS and the cytoplasmic protein GAPDH. Total (T), cytoplasmic (C), nuclear (N) and insoluble
nuclear protein (NI) fractions are shown (top). Quantiﬁcation of the relative abundance of TDRD3 in each fraction is presented in a bar graph (bottom) (D).
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transfection-induced stress.
In order to conﬁrm the identity of these TDRD3-containing
foci, HeLa cells were exposed to different stress stimuli
and double IF experiments were performed using TDRD3
antibodies in combination with an antibody directed against
the RNA-binding protein TIA-1, a well-accepted marker of
cytoplasmic SGs. Upon oxidative, heat and osmotic shocks,
endogenous TDRD3 was redistributed to cytoplasmic SGs,
where it colocalized with TIA-1 (Fig. 3A). For simplicity,
Figure 3. TDRD3 localizes to cytoplasmic stress granules during stress response. HeLa cells cultured on glass cover slips were left untreated (C) or exposed to
oxidative stress (Ars; 0.5 mM sodium arsenite for 30 min), heat shock (HS; 438C for 30 min) or high-osmolarity medium (Osm; 1 M sorbitol in DMEM for 1 h
followed by a 30-min recovery in normal DMEM). The cells were ﬁxed and immunostained with TDRD3 and TIA-1 antibodies to detect the endogenous proteins
(A). Cells were stressed with 0.5 mM sodium arsenite (Ars) for 30 min, followed by immunostaining of both TDRD3 and FMRP endogenous proteins (B).
To visualize G3BP, a GFP fusion construct was transfected into cells 24 h prior to immunoﬂuorescence analysis. Cells were left untreated (C) or exposed
to oxidative stress (Ars) for 30 min, followed by immunostaining for endogenous TDRD3 (C). Cells were stressed with 0.5 mM sodium arsenite for the indicated
time length before their ﬁxation and double immunoﬂuorescence with TDRD3 and TIA-1 antibodies (D). HeLa cells were either left untreated (C) or stressed for
30 min with 0.5 mM sodium arsenite (Ars). After ﬁxation, endogenous TDRD3 and GW182 (a marker of P-bodies) were detected by ﬂuorescence
microscopy (E).
3060 Human Molecular Genetics, 2008, Vol. 17, No. 19sodium arsenite was used in all subsequent experiments to
induce cellular stress response. The FMRP is another protein
that is well-known to relocalize to SGs (57,58), and it was
recently found to interact with TDRD3 (U. Fischer, personal
communication). Accordingly, colocalization of TDRD3 and
FMRP into SGs following stress was also observed
(Fig. 3B). Relocalization of TDRD3 in SGs was further con-
ﬁrmed by its colocalization with a GFP fusion of another com-
ponent of these granules, the RNA-binding protein G3BP
(Fig. 3C, bottom, Ars). G3BP overexpression is known to
induce the formation of SGs, even in the absence of any
other stress stimuli (59), and as anticipated, TDRD3 was
also observed in G3BP-induced SGs (Fig. 3C, top, C). Impor-
tantly, TDRD3 was detectable in SGs as early as 10 min fol-
lowing sodium arsenite treatment (Fig. 3D), which is
comparable to the kinetics of TIA-1 relocalization to SGs
(60). However, the use of ﬁner live cell imaging approaches
will be required to determine the precise kinetics of TDRD3
recruitment to SGs. Finally, TDRD3 did not localize to other
cytoplasmic mRNA foci, such as processing bodies, as
shown by the absence of colocalization with GW182
(Fig. 3E), an RNA-binding protein resident of these structures
(61,62). Taken together, our results indicate that TDRD3 is a
novel component of cytoplasmic SGs.
TDRD3 is associated with translating polyribosomes
SGs are considered to be stalled aggregates of 48S preinitia-
tion complexes and contain a number of translation factors,
including eIF3, eIF4E, eIF4G, PABP-1 and FMRP (50). In
contrast to TIA-1, which is not normally associated with the
translational machinery (63), FMRP can be found on polyribo-
somes (64,65). To determine if TDRD3 is associated with
translational complexes, post-nuclear supernatants were sub-
jected to velocity sedimentation through sucrose gradients
and each collected fraction was analyzed by western blot for
the presence of TDRD3 (Fig. 4, control panels). Using this
protocol, it is possible to resolve free ribosomal subunits
(40S and 60S) and monomers (80S) from actively translating
polysomes, which sediment towards the bottom of the gradi-
ent, as conﬁrmed by the distribution of the ribosomal S6
protein in each fraction (Fig. 4, S6 panel). Strikingly,
TDRD3 was found distributed in both the light and the
heavy sedimenting fractions of the sucrose gradient, following
a pattern similar to what is observed for FMRP (Fig. 4,
respective panels). Heat shock protein 72 (Hsp72) was used
as a negative control in these experiments as it should not
be associated with ribosomes. These results indicate that
TDRD3 is associated with actively translating polyribosomes
in cycling HeLa cells.
Under stress conditions such as heat shock or arsenite,
FMRP shifts away from polyribosomes, which are largely
disassembled due to inhibition of translation initiation
(50,57,58,66). Thus, we next determined if TDRD3 would
follow the same pattern in ribosome proﬁles following stress
induced by arsenite treatment (Fig. 4, Arsenite panels).
HeLa cells were incubated with sodium arsenite as above,
before being subjected to velocity sedimentation through
sucrose gradients. Each collected fraction was then analyzed
by western blot for the presence of TDRD3. As expected,
polysome peaks were almost undetectable following arsenite
treatment, and this was associated with an increase of the
80S monomer fraction (Fig. 4, Arsenite UV proﬁle). Under
these stress conditions, the bulk of TDRD3 was found
mainly associated with monomeric ribosomes and lighter frac-
tions, again following the pattern previously reported for
FMRP (Fig. 4, respective panels). Taken together, these
results suggest that TDRD3’s function may be at the level of
translational regulation.
The Tudor domain is both essential and sufﬁcient for
TDRD3 translocation to cytoplasmic SGs
To identify which part of TDRD3 was important for its local-
ization to SGs, a series of myc epitope-tagged deletion con-
structs was generated (Fig. 5A). The fusion proteins were
expressed in HeLa cells and IF microscopy was performed
using myc antibodies (Fig. 5B and E). As its endogenous
counterpart, full-length myc-tagged TDRD3 localized pre-
dominantly to the cytoplasm with a weaker diffuse nuclear
staining (Fig. 5Ba). Overall, the intracellular distribution pat-
terns of deletion mutants were similar to that of full-length
TDRD3 (Fig. 5Bb–e), although a certain degree of variation
was observed depending on expression levels. A second
series of constructs was engineered to express speciﬁc con-
served domains of the TDRD3 protein (Fig. 5A). The pre-
dicted molecular weight of these myc-tagged TDRD3
isolated domains ranges from 4 to 36 kDa, which means that
they are likely to diffuse freely between the cytoplasm and
Figure 4. TDRD3 is associated with polyribosomes in HeLa cells. Cyto-
plasmic extracts were prepared from HeLa cells grown in normal conditions
and centrifuged on a 10–60% w/w linear sucrose gradient. Fractions were col-
lected and analyzed by western blot with antibodies against the ribosomal S6
protein and FMRP (as positive controls), TDRD3, and Hsp72 (as a negative
control) (Control panel). Cytoplasmic extracts from HeLa cells treated with
0.5 mM sodium arsenite for 30 min were analyzed in parallel and the collected
fractions were analyzed by western blot using the ribosomal L28 protein as
positive control (Arsenite panel). Fractions from the top to the bottom of
the gradient are shown from left to right. The positions of free small (40S)
and large (60S) ribosomal subunits, monosomes (80S), and polysomes are
indicated in each proﬁle. The band corresponding to TDRD3 is indicated by
a ‘dot’ on the side of the respective panels. Additional bands detected
on the immunoblots represent non-speciﬁc reactivity with our polyclonal
antibody.
Human Molecular Genetics, 2008, Vol. 17, No. 19 3061Figure 5. The Tudor domain of TDRD3 is both required and sufﬁcient for its recruitment to stress granules. Diagram showing the various myc epitope-tagged
TDRD3 deletion mutants used in this study (A). HeLa cells were transiently transfected with each deletion mutant. Twenty-four hours post-transfection, cells
were left untreated and labeled for immunoﬂuorescence with TIA-1 and myc antibodies to detect endogenous TIA-1 protein and recombinant myc-tagged pro-
teins (B). Alternatively, transfected cells were treated with 0.5 mM sodium arsenite for 30 min. Indirect immunoﬂuorescence staining was performed as described
above (C). HeLa cells were transiently transfected with constructs expressing recombinant myc-tagged Tudor domain of SMN, SPF30 or TDRD3. Twenty-four
hours post-transfection, cells were treated with 0.5 mM sodium arsenite for 30 min. Indirect immunoﬂuorescence staining was performed using myc and TIA-1
antibodies (D). Total cell lysates of HeLa cells transiently expressing myc-tagged TDRD3 deletion mutants, as well as SMN and SPF30 Tudor domains, were
immunoblotted with myc antibodies to conﬁrm expression (E).
3062 Human Molecular Genetics, 2008, Vol. 17, No. 19the nucleus. As expected, expression of TDRD3’s isolated
domains in HeLa cells resulted in both cytoplasmic and
nuclear diffused staining (Fig. 5Bf–i). Finally, in contrast
with G3BP, overexpression of TDRD3 (or any deletion
mutant) did not signiﬁcantly induce the formation of SGs in
the absence of external stress stimuli. Taken together, these
experiments did not permit the clear identiﬁcation of a
domain inﬂuencing normal TDRD3 subcellular localization.
We next assessed whether each TDRD3 deletion mutant had
retained the property of being relocalized to cytoplasmic SGs
following sodium arsenite treatment (Fig. 5C). Intriguingly,
overexpression of any myc-tagged TDRD3 proteins harboring
the DUF1767/OB-fold motifs was toxic for cells when they
were put under stress conditions. In order to circumvent
this problem, we generated additional deletion mutants
of TDRD3, lacking the N-terminal DUF1767/OB-fold
domains [Fig. 5A; TDRD3 D(DUF/OBþUBA) and TDRD3
D(DUF/OBþTdr)]. These mutants displayed an intracellular
distribution that was identical to their respective
N-terminal-containing counterparts in the absence of stress
(data not shown). Following arsenite treatment, DDUF/OB,
DN328 and D(DUF/OBþUBA) all still relocalized to SGs,
albeit to varying degrees (Fig. 5Ca–c). In contrast, D(DUF/
OBþTdr) was not detectable in cytoplasmic SGs following
stress stimuli (Fig. 5Cd), which suggest a requirement for
the Tudor domain in this process. Accordingly, when
TDRD3’s isolated domains were tested, only the Tudor
domain (Tdr) was found to be sufﬁcient for relocalization to
SGs upon arsenite treatment (Fig. 5Ce–h). Interestingly, the
central linker fragment (amino acids 328–647) was redistrib-
uted almost entirely to the cytoplasm following arsenite treat-
ment (compare Fig. 5Bh with 5Cg), suggesting that this region
may contain an element favoring its export from the nucleus to
the cytoplasm upon stress. Taken together, these results show
that the Tudor domain of TDRD3 is both required and sufﬁ-
cient for its recruitment to cytoplasmic SGs during cellular
stress response, although the central linker region may also
contribute to this process by promoting nuclear-cytoplasmic
translocation.
SMN, which also harbors a Tudor domain, was previously
reported to relocalize to SGs upon stress (67). Hence, we
next wanted to determine whether this feature was unique to
the Tudor domain of TDRD3 or common to other known
Tudor domains. To investigate this possibility, HeLa cells
were transiently transfected with the isolated Tudor domain
of SMN, SPF30 or TDRD3 fused to a myc epitope tag
(Fig. 5D and E). Twenty-four hours post-transfection, cells
were treated with sodium arsenite and immunostained with
myc antibodies. The Tudor domain of TDRD3 was effectively
recruited to SGs upon stress (Fig. 5D). However, neither SMN
nor SPF30’s Tudor domain localized to SGs under the same
conditions (Fig. 5D). These observations therefore suggest
Figure 5. Continued.
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involves interactions that are mediated by, and that are unique
to its Tudor domain.
Identiﬁcation of TDRD3 Tudor domain interactors
In order to begin the identiﬁcation of proteins interacting
speciﬁcally with the Tudor domain of TDRD3, a
glutathione-S-transferase (GST) pull-down was performed
using HeLa total cell extracts. A recombinant fusion protein
was generated, consisting of GST fused to the C-terminal
region of TDRD3 (amino acids 647–744) encompassing the
Tudor domain (GST-TDRD3-Tdr). GST-TDRD3-Tdr and
GST alone were then coupled to glutathione-agarose and
used as afﬁnity columns to pull down interacting proteins
from HeLa cell lysates. The retained proteins were resolved
by SDS–PAGE and stained with Coomassie Blue.
GST-TDRD3-Tdr bound several polypeptides that were not
bound by GST alone (data not shown). Five of these speciﬁc
protein bands were excised from the gel and subjected to
mass spectrometry identiﬁcation (68). The top matches
obtained for each band are EWS, FUS, DDX3, SERBP1 and
EEF1A1 (see Table 1 for details). Remarkably, all these pro-
teins have known roles in RNA handling, which reinforces
our hypothesis that TDRD3 likely functions in post-
transcriptional processes.
Interestingly, EWS was previously shown to interact
with the Tudor domain of SMN (69), although arginine
methylation was not a requirement for binding in this case.
A Caenorhabditis elegans ortholog of SERBP1 was also
found to interact with SMN (70). Finally, FUS is present in
a complex with SMN and the NFAR proteins (71), although
a direct interaction between SMN and FUS was not reported.
These observations prompted us to verify if all the proteins
identiﬁed in our screen were also able to bind the Tudor
domain of SMN. These experiments revealed that EWS and
FUS were also interacting with SMN-Tdr, but the interactions
with DDX3 and EEF1A1 were speciﬁc to TDRD3 (Goulet and
Co ˆte ´, unpublished data). SERBP1 was not tested in these
experiments. The functional relevance of each of these inter-
actions in the context of the full-length protein will need to
be addressed in future studies.
Direct contact with methylated arginines contributes
to TDRD3 relocalization to SGs
All the identiﬁed proteins also contain RG-rich motifs, which
represent common target sites for protein arginine methyl-
transferases (Table 1). In fact, the presence of methylated argi-
nines in EWS and FUS has been documented (6,7,72), and we
have also detected modiﬁed arginines in our proteomic analy-
sis (data not shown). Since the Tudor domain of TDRD3 can
speciﬁcally recognize methylated arginine motifs in proteins
(16,17), we speculated that TDRD3 might be recruited to
SGs through methyl-dependent interactions with one or more
of its binding partners. Previous studies have demonstrated
that an E134K amino acid substitution in the Tudor domain
of SMN abolished its interaction with arginine-methylated
polypeptides (17). This amino acid is conserved in the
Tudor domain of TDRD3 and corresponds to residue E691.
Table 1. Potentially methylated proteins involved in RNA processing interact with the Tudor domain of TDRD3
MW SDS–
PAGE
Protein name (GenPept acc. no) Score RG-motifs Known or putative function(s)
a Calc. mass
(kDa)
p80 Ewing sarcoma breakpoint region 1
(NP_005234)
70.26 19  RGG RNA-binding protein (transcription and
pre-mRNA splicing machineries)
68.592
300RGRGRGG
306
314RGGRGGGRGG
323
p75 DEAD/H box-3 (NP_001347) 40.17 10  RG RNA splicing and transport 73.244
121RGG
123
p60 Fus (NP_004951) 40.15 2  RGG RNA splicing and nuclear/cytoplasmic
shutting
53.377
216RGGRGRG
222
245RGRGGGRGGRGG
256
380RGGGNGRGGRG
RGGPMGRGG
399
475RRGGRGGYDRGGYRGRGG
DRGGFRGGRGGGDRGG
508
p50 Eukaryotic translation elongation factor
1 alpha 1 (NP_001393)
150.19 2  RG Translation anchoring 50.141
p35 SERPINE1 mRNA-binding protein 1
(NP_001018077)
60.11 1  RG, 1  RGG Regulation of mRNA stability 44.966
163RGRGGLGRGRG
GRGRGMGRG
182
346RGGRGGRGGRGRGGR
360
HeLa cells were lysed and incubated with either puriﬁed recombinant GST (as a control) or GST-TDRD3-Tdr proteins coupled to glutathione-agarose
(see Materials and Methods). The polypeptides speciﬁcally pulled down by TDRD3-Tdr, that were not pulled down by GST alone, were excised from the
gel and sent for mass spectrometry analysis and identiﬁcation. Sequencing data were analyzed using the Sequest software and only the top match
obtained for each band is listed (highest score). Potentially methylated RG-rich motifs found in the amino acid sequence (GenPept database) of each
protein are also depicted, as well as their known or putative function (see text for details and references).
asee text for reference.
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TDRD3 Tudor domain would also abolish its capacity to inter-
act with methylated arginines, an in vitro binding assay was
used, with synthetic (RG)4 biotinylated peptides containing
either no modiﬁed amino acids or symmetrically dimethylated
arginines (sDMA). Puriﬁed recombinant GST-TDRD3-Tdr
fusion proteins were incubated with the biotinylated peptides
coupled to streptavidin-agarose. As previously reported (17),
puriﬁed GST-TDRD3-Tdr bound to sDMA peptide columns
in a dose-dependent manner, but did not bind the unmethy-
lated peptide (Fig. 6A, compare lanes 5–7 with lanes 2–4).
Remarkably, this binding was completely abolished with the
introduction of the E691K mutation in the TDRD3 Tudor
domain (Fig. 6A, GST-TDRD3-Tdr E691K). This result con-
ﬁrms that the Tudor domain of TDRD3 behaves as a methyl-
binding protein module similar to that of SMN, in which the
E691 residue is crucial for direct contact with dimethylated
arginine motifs. This TDRD3 mutant was next used to deter-
mine if this methylarginine binding surface was important
for recruitment to SGs. HeLa cells were transfected with a
myc-tagged TDRD3 Tudor fragment containing the E691K
point mutation. Twenty-four hours post-transfection, cells
were stressed with sodium arsenite and labeled for IF with
myc antibodies. Strikingly, the introduction of the E691K
mutation in the Tudor domain of TDRD3 reduced its recruit-
ment to SGs upon stress by at least 50% (Fig. 6B). This obser-
vation suggests that TDRD3’s recruitment to SGs is likely
mediated through speciﬁc protein–protein interactions invol-
ving methylated arginines.
In order to fulﬁll this role, an interacting protein would have
to satisfy at least two conditions. First, the protein has to be
relocalized to SGs upon stress. Second, its interaction with
TDRD3 must be affected by the E691K mutation. To verify
the ﬁrst criteria, IF microscopy was performed using commer-
cially available antibodies for EWS, DDX3, EEF1A1 and
FUS, or an epitope-tagged version of SERBP1 (myc)
(Fig. 6C). Strikingly, only DDX3 and SERBP1 relocalized sig-
niﬁcantly to SGs following arsenite treatment, while the other
proteins showed little to no response to the stress stimuli
(Fig. 6C, respective panels). To verify the second condition,
a GST-TDRD3-Tdr pull down was performed as above
using total HeLa cell lysates as input, and the retained proteins
were analyzed by western blot with commercially available
antibodies speciﬁc to EWS, DDX3, FUS and EEF1A1
(Fig. 6D, lane 3). The E691K mutation completely prevented
the interaction with EWS and FUS, while reducing binding to
DDX3 and EEF1A1 by 50 and 90%, respectively (Fig. 6D,
lane 4). We have not yet assessed if the interaction of
SERBP1 with TDRD3 was also affected by the presence of
this mutation due to antibody availability. Taken together,
these results identify DDX3 as a good candidate to mediate
the recruitment of TDRD3 to SGs (or vice versa). Moreover,
these experiments show that the methyl-binding surface of
TDRD3’s Tudor domain is important for this process.
Arginine methylation: a general regulator of SG
assembly/disassembly?
A recent study uncovered a new subset of smaller cytoplasmic
foci that are clearly distinct from SGs, which contain
FMRP (73). FMRP is an RG-rich protein that is an in vitro
substrate for protein arginine methyltransferases (74). FMRP
relocalizes to bona ﬁde SGs following treatment with
various stimuli, and it was suggested that arginine methylation
may regulate its translocation from smaller cytoplasmic foci
into SGs by promoting its heterodimerization with fragile X
mental retardation-related protein 1 (FXR1p) (73). Since this
mechanism is reminiscent of what we propose for the recruit-
ment of TDRD3 along with DDX3 and/or SERBP1 to SGs, we
wanted to determine if arginine methylation may play a
general role in the assembly of SGs.
HeLa cells were grown for 20 h in the presence of 1 mM
50-deoxy-50-methylthioadenosine (MTA), a well-characterized
general inhibitor of methylation (9). Following this pre-
treatment, which reduced steady-state arginine methylation
levels by 50% (Fig. 7C), cells were incubated with sodium
arsenite and IF microscopy was performed with antibodies
against TDRD3 and TIA-1 to monitor the formation of SGs.
First, it was conﬁrmed that the MTA treatment alone did not
cause the formation of SGs (data not shown). As observed in
non-treated HeLa cells (see time-course in Fig. 3D), TDRD3
was detectable in nascent SGs as early as 10–15 min after
the addition of arsenite in mock-treated cells, and TIA-1
after 20 min (data not shown). SGs containing both
TDRD3 and TIA-1 were present in 100% of cells after
30 min. Similarly, cells pre-treated with the methylation
inhibitor MTA all contained TDRD3- and TIA-1-positive
SGs after 30 min of stress stimulus, although small differences
were observed at shorter time points. Speciﬁcally, recruitment
of TDRD3 to SGs was delayed to some extent, while more
cells with TIA-1-containing SGs could be clearly discerned
after 15 min (data not shown). Thus, reducing arginine
methylation levels by 50% did not prevent assembly of
SGs, although the precise composition of these granules
seemed to be altered.
Another series of stressed cells (pre-treated or not with
MTA) was immunostained for TDRD3 at various time
points after being returned to normal growth media. As
expected from previous studies (75), SGs ﬁrst decreased in
number, but increased in size, and then gradually disappeared
following stress withdrawal, so that they were no longer
detectable after 120–150 min in mock-treated cells (Fig. 7A,
DMSO panels). In contrast, the number of SG-positive cells
increased by 6-fold in cells pre-treated with the methylation
inhibitor MTA after 150 min of recovery (Fig. 7A, MTA
panels, and 7B). These observations were also conﬁrmed
using TIA-1 as a SG marker (data not shown). Taken together,
our experiments support a role for methylation in regulating SG
dynamics and composition, potentially by regulating protein–
protein interactions and impacting on SG disassembly.
DISCUSSION
We report here the ﬁrst characterization of TDRD3, a novel
Tudor-containing protein associated with poor prognosis of
estrogen receptor-negative breast cancers (48). Our ﬁndings
identify TDRD3 as a novel component of cytoplasmic SGs,
where it relocalizes following various cellular stresses, including
oxidative, heat and osmotic shocks. We also show that TDRD3
Human Molecular Genetics, 2008, Vol. 17, No. 19 3065Figure 6. Direct contact with methylated arginines contributes to TDRD3 relocalization to SGs. Biotinylated (RG4) peptides containing either unmethylated
arginines or symmetrically dimethylated arginines (sDMA) were bound to streptavidin-agarose and used as afﬁnity columns to measure the binding of puriﬁed
GST fusion SMN and SMN E134K (as controls) and/or TDRD3 and TDRD3 E691K Tudor domains. The bound GST-Tdr fusion proteins were resolved by
SDS-PAGE, transferred to a PVDF membrane, and detected by immunoblotting using GST antibodies (A). HeLa cells were transiently transfected with con-
structs expressing recombinant myc-tagged wild type or mutated (E691K) TDRD3 Tudor domain. Twenty-four hours post-transfection, cells were treated
with 0.5 mM sodium arsenite for 30 min. Indirect immunoﬂuorescence staining was performed using myc and TIA-1 antibodies (B). HeLa cells were either
left untreated (C) or treated with 0.5 mM sodium arsenite for 30 min (Ars). Cells were then labeled for immunoﬂuorescence with EWS (a and b), DDX3 (c
and d), FUS (e and f), or EEF1A1 (g and h) in combination with TIA-1 antibodies to detect endogenous proteins. HeLa cells transiently transfected to
express myc-tagged SERBP1 (i and j) were either left untreated (C) or stressed as described above (Ars), before being immunostained with TDRD3 and
myc (SERBP1) antibodies (C). HeLa cells from 2  150 mm plates were lysed and incubated with puriﬁed recombinant GST (as a control), GST-TDRD3-Tdr
or GST-TDRD3-Tdr E691K proteins coupled to glutathione-agarose. The retained proteins were resolved by SDS-PAGE, transferred to PVDF, and immuno-
blotted with the speciﬁed antibodies to conﬁrm mass spectrometry identiﬁcations. The membrane was stained with Ponceau Red prior to immunoblotting,i n
order to show the GST-fusion proteins (D).
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conditions. A proteomic screen led to the identiﬁcation of ﬁve
novel TDRD3 interacting partners with known or putative
roles in various aspects of RNA metabolism. Moreover, all
these TDRD3 interacting proteins harbor RG-rich motifs that
represent consensus sites for protein arginine methyltransferases.
Our experiments revealed that two of these proteins, SERBP1
and DDX3 [a gene associated with Sertoli-cell-only (SCO) syn-
drome], are also novel constituents of cytoplasmic SGs. The
Tudor domain of TDRD3 was both required and sufﬁcient for
its relocalization to SGs. Speciﬁcally, the use of a conserved
mutation helped us demonstrate that the methyl-binding
surface in the Tudor domain of TDRD3 is involved in this
process. Finally, we found that arginine methylation may be a
general regulator of SG dynamics and protein composition.
TDRD3 is a novel component of cytoplasmic SGs
We report here that the novel Tudor-containing protein
TDRD3 relocalizes with TIA-1, a well-known SG marker
upon arsenite treatment, heat shock and osmotic shock
(Fig. 3A). TDRD3 also colocalized in SGs with FMRP follow-
ing arsenite treatment, and it can be recruited to
transfection-induced SGs upon GFP-G3BP overexpression
(Fig. 3B and C, respectively). In contrast, TDRD3 did not
colocalize with processing body (also known as GW bodies)
markers under any conditions tested here (Fig. 3E and data
not shown). TIA-1 is considered to be a crucial mediator of
SG assembly, as it is thought to promote aggregation
through its prion-like glutamine-rich C-terminal domain
(60). FMRP is also thought to participate, along with TIA-1,
Figure 7. Arginine methylation and SG dynamics. HeLa cells grown on cover slips were stressed with 0.5 mM sodium arsenite for 30 min. Cells were then
returned to normal growth media and prepared for TDRD3/TIA-1 immunostaining after the indicated incubation periods (A). The experiment was repeated
twice using different batches of cells. At least 500 cells were counted for each time point and condition. Fold increase of SG-positive cells in the MTA-treated
cells when compared the DMSO-treated cells is depicted in a bar graph (B). Cell extracts prepared from HeLa cells grown in the presence (þ) or the absence (2)
of the general methylation inhibitor MTA were immunoblotted with the SYM10 antibody to conﬁrm the reduction in steady-state arginine methylation levels.
The same extracts were immunoblotted with actin antibodies to control for equal loading (C).
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(50). Since we found that TDRD3 can be detected in SGs con-
comitantly or even prior to TIA-1 (Fig. 3C), it may participate
in the early phases of SG assembly. This is also consistent
with the association of TDRD3 with polyribosomes (Fig. 4),
since SG assembly involves stalled translation initiation com-
plexes, polysome disassembly and mRNP aggregation (50).
However, TDRD3 did not signiﬁcantly induce SG formation
on its own in the absence of additional stress stimuli, in con-
trast to TIA-1, G3BP and FMRP, which are all thought to
physically nucleate SG assembly (50). In fact, our experiments
suggest that TDRD3 may participate in the SG disassembly
process by engaging in protein–protein interactions regulated
by arginine methylation (see below), although further exper-
iments will be required to fully conﬁrm this hypothesis.
TDRD3 interacts with proteins involved in RNA
handling and/or metabolism
We have uncovered, using a large-scale Tudor domain pull
down approach, ﬁve novel protein-binding partners for
TDRD3 (Table 1). Strikingly, we found that two of these pro-
teins, SERBP1 and DDX3, also relocalize to SGs following
sodium arsenite treatment, although we cannot rule out that
some of the other TDRD3 binding partners may still transi-
ently associate with SGs (Fig. 6C). In addition, each of the
newly identiﬁed TDRD3 interactors has previously been
linked with post-transcriptional regulatory processes.
EEF1A1 is a translation initiation factor that has been shown
to participate in the anchoring of speciﬁc mRNAs to the cyto-
skeleton (76), while DDX3 has been implicated in pre-mRNA
splicing, nuclear export, mRNA transport and translation
initiation (77–85). TDRD3 also interacts with FMRP and
associates with translating polyribosomes. Taken together,
these observations strongly suggest that TDRD3 may function
as a translational regulator.
In contrast, SERBP1 (a.k.a. PAI-RBP1) has been suggested
to play a role in mRNA stability (86), while EWS and FUS
have both been implicated in alternative splicing regulation
(87–93). Intriguingly, TDRD3 has been identiﬁed in a proteo-
mic screen of proteins associated with spliceosome complexes
(94). However, our experiments did not provide any indi-
cations to support a role for TDRD3 in splicing (Goulet and
Co ˆte ´, unpublished data). Further experimentation will be
needed to establish its function in this precise mechanism.
The Tudor domain of TDRD3 is both required and
sufﬁcient for its localization to SGs
All the proteins identiﬁed in our GST-TDRD3-Tdr pull down
are either known or are very likely to contain methylated argi-
nines (Table 1). This is consistent with our previous studies,
which demonstrated that the Tudor domain of TDRD3 can
speciﬁcally recognize methylated arginine motifs in proteins
(17). Since DDX3 and SERBP1 are the only proteins that
could be detected in SGs, these proteins are good candidates
to mediate the methyl-dependent recruitment of TDRD3 to
these structures. In this study, we have presented several evi-
dences supporting this model. First, thorough deletion
mapping clearly showed that the Tudor domain of TDRD3
is both sufﬁcient and required for its localization to SGs,
although the central linker region may also contribute to this
process by promoting nuclear-cytoplasmic translocation
(Fig. 5). Second, a single E-.K substitution (E691K) in the
methylarginine-binding interface of TDRD3’s Tudor domain
is sufﬁcient to greatly reduce its recruitment to SGs
(Fig. 6B). Third, this same E691K mutation also reduces the
interaction with DDX3 (Fig. 6D). Finally, general methylation
inhibitors perturbed the dynamics of SG assembly/disassembly
as well as their composition (Fig. 7 and see below).
Arginine methylation and SG dynamics
A simple prediction from our model would have been for
methylation inhibitors to prevent or at least reduce the recruit-
ment of TDRD3 to SGs, potentially even preventing their for-
mation. In contrast, our results show that MTA treatment did
not prevent SG assembly, as 100% of cells contained a
normal number of SGs 30 min after arsenite treatment (data
not shown). However, we cannot eliminate the possibility
that a 50% reduction in overall arginine methylation may
not be sufﬁcient to observe a drastic effect. Moreover, our esti-
mate of the efﬁciency of the MTA treatment does not take into
account the different turnover rate of all the proteins that could
be involved in SG assembly. Nevertheless, we did observe a
tendency for TDRD3 and TIA-1 to no longer follow the
same kinetics of recruitment as seen at early time points of
SG formation. SGs are highly dynamic structures with com-
ponents rapidly and continuously shuttling in and out (75).
Hence, more in-depth studies using Fluorescence Recovery
After Photobleaching experiments or similar approaches
would be required to conﬁrm and quantify these effects. Fol-
lowing the same idea, a longer time window may explain
why we were able, under the same conditions of MTA treat-
ment, to observe more profound differences in the recovery
phase after the return to normal growth conditions (Fig. 7).
Taken together, our results can be reconciled by proposing a
role for arginine methylation in the regulation of many
protein–protein interactions (including but not limited to the
TDRD3/DDX3 interaction) important for SG dynamics. This
is consistent with, and expands, the model proposed by
Denman and colleagues for the recruitment of FMRP to SGs
(73). Finally, this interpretation is also reminiscent of the
role that arginine methylation plays in other cellular processes;
for instance, the assembly of spliceosomal snRNPs, where it
serves to promote the efﬁcient and speciﬁc assembly of
large ribonucleoprotein macromolecular complexes.
Tudor domains and RNA granules
Several recent studies have provided links between Tudor
domain-containing proteins and various types of ‘RNA gran-
ules’. We have recently uncovered a novel interaction
between the Tudor domain of SMN and KSRP, a KH-type
RNA-binding protein that colocalizes with SMN in neuronal
RNA granules (95). Moreover, each of the novel TDRD3
interactors (including FMRP) have also been identiﬁed as
components of neuronal RNA granules (51,79,81,96–98).
Neuronal granules are considered to be highly related, both
in composition and function, to cytoplasmic SGs (98), since
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ally silent state, along dendrites and axons of neuronal cells
(99). Whether TDRD3 plays a role in regulating translation
within SGs and/or neuronal RNA granules will require
further experimentation. In fact, SMN has been shown to relo-
calize to SGs per se, although a functional requirement for its
Tudor domain was not established in these studies (67). In our
hands, relocalization to SGs was a property unique to the
Tudor domain of TDRD3, as the isolated Tudor domains of
SMN and SPF30 were not found in SGs under any of the con-
ditions tested here (Fig. 5D and data not shown). Nevertheless,
it is possible that the association of SMN with SGs may be
cell-type-speciﬁc, more transient or may require other
domains of the protein (e.g. its C-terminal dimerization
domain).
Studies in both Drosophila and mouse have uncovered a
crucial role for Tudor domain-containing proteins in germline
development and polar granules architecture (100–103). Polar
or germ granules are specialized structures containing many
mRNAs and RNA-binding proteins needed for germ cell for-
mation (104), and it was suggested that several parallels
could be drawn between these structures and SGs (98). Sm
proteins and PRMT5 were also found to localize to polar gran-
ules and to be essential for Drosophila germ cell speciﬁcation
and maintenance (105,106). Most importantly, Gonsalvez
et al. (106) showed that absence of PRMT5 in ﬂies results
in the loss of arginine methylation on Sm as well as other pro-
teins, producing a phenotype resembling that of TUDOR
mutants, which suggests that methyl-dependent interactions
are crucial for this phenomenon. Lastly, DDX3 is thought to
play a role in the early phase of spermatogenesis (see
below), thus it will be interesting in future studies to look
for a role of TDRD3 in germ cell biology.
TDRD3, SGs and human disease?
TDRD3 can be linked with human genetic diseases. First,
DDX3 has a Y-linked homolog (.94% homology) that is
also known as DBY. The peptides identiﬁed in our proteomic
analysis do not allow us to determine if the protein we have
isolated was DDX3X or DDX3Y (data not shown). This
gene is located in the azospermia factor a (AZFa) region on
the human Y chomosome (Yq11.21). Deletion of this Y inter-
val is known to be a major cause for the occurrence of a severe
testicular pathology associated with a complete germ cell loss,
the SCO syndrome, and speciﬁc loss of DBY expression has
been documented and correlated with this human pathology
(107–109). Secondly, TDRD3 was found to interact with
FMRP, the gene associated with fragile X mental retardation
syndrome (U. Fischer, personal communication). Thirdly,
TDRD3 was identiﬁed as one of the top hits in a screen for
genes strongly correlated with poor post-operative prognosis
of estrogen receptor-negative breast cancers (48). Interest-
ingly, several of the proteins identiﬁed in our interaction
screen have links with cancer. For example, EWS and FUS
are both involved in recurrent chromosome translocations
that result in novel fusion oncoproteins associated with
many forms of sarcomas (110). These resulting fusion proteins
have aberrant transcriptional function compared with their
wild-type counterparts and thereby result in a variety of
altered cellular properties that contribute to the tumorigenic
process. A role for TDRD3 in transcription was never postu-
lated, but a signiﬁcant proportion (30%) of total TDRD3
can be detected in the nucleus (Fig. 2). Thus, it would be inter-
esting to investigate the functional relevance of TDRD3 inter-
action with common sarcoma-associated EWS and FUS
oncoprotein fusions. EEF1A1 was found to be overexpressed
in rat mammary adenocarcinomas and its expression level cor-
relates with metastasis (111 and references therein). Most
strikingly, an oncogenic role for DDX3 was recently shown
to be important for breast cancer biogenesis (112). Other com-
ponents of SGs, including HuR, have also been linked with
cancer in many ways (113). Finally, the Tudor domain of
TDRD3 is highly conserved with the Tudor domain of
SMN, the causative gene of spinal muscular atrophy (17).
Whether TDRD3 participates in these pathways, and
whether it does so in the context of SGs, remains unclear
and will be the focus of future studies.
MATERIALS AND METHODS
Cell culture and transfections
The human HeLa cervical carcinoma cell line was purchased
from ATCC (Manassas, VA) and grown as a monolayer in
DMEM medium supplemented with 1 mM sodium pyruvate,
50 IU/ml penicillin, 50 mg/ml streptomycin and 10% fetal
calf serum (Wisent, St-Bruno, QC, Canada). Cells were trans-
fected with DNA plasmids using the Lipofectamine Plus
reagent (Invitrogen, Burlington, ON, Canada) according to
manufacturer’s instructions.
DNA constructs
Total RNA was extracted from HeLa cells using Trizol reagent
(Invitrogen) according to manufacturer’s instructions. RNA
concentration was measured with a spectrophotometer, and
RNA quality was assessed by agarose gel electrophoresis.
First strand cDNA synthesis was performed using 5 mgo f
total RNA and the avian myeloblastosis virus reverse tran-
scriptase (Promega, Madison, WI) with an oligo-dT primer.
cDNAs were ampliﬁed using oligonucleotides designed to
introduce either full-length or deletion mutants of TDRD3
(DDUF/OB, DN328, DUBA, DTdr, D(DUF/OBþUBA),
D(DUF/OBþTdr), DUF/OB, UBA, Central linker and Tdr)
in frame with a myc tag into the EcoRI and XhoI restriction
sites of the pCMV-Myc expression vector (Clontech Labora-
tories Inc., Mountain View, CA). The TDRD3 Tudor (Tdr;
amino acids 647–744) fragment was also inserted into the
EcoRI/XhoI sites of the pGEX-4T2 vector (GE Healthcare,
Piscataway, NJ). The TDRD3 Tudor E691K mutation was
introduced using overlap extension mutagenesis (114) with
the following mutagenic oligonucleotides: 50-ggaaactataaaga
ggtgctactg-30 and 50-cagtagcacctctttatagtttcc-30, while using
TDRD3-speciﬁc primers as ﬂanking oligonucleotides. The
mutated fragment was then inserted into the EcoRI and XhoI
restriction sites of both the pCMV-Myc and the pGEX-4T2
vectors. The human SMN Tudor domain was ampliﬁed using
the following oligonucleotides: 50-ccggaattcgcagtggaaagttgggg
acaaa-30 and 50-ccggaattcttaattagctacttcacagattgg-30,a n di n s e r t e d
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(Invitrogen) containing the myc epitope tag sequence (115).
Cloning of the wild-type and E134K SMN Tudor domains
into the pGEX-4T2 vector have been previously described
(17). The Tudor domain of SPF30 was ampliﬁed from the
SPF30 expression vector (17) by using PCR with the 50-ttttg
aattcttctactcaacctactcattcatgg-30 and 50-ttttctcgagttactcctttg
ccttccttccttctt-30 oligonucleotides, and the ampliﬁed DNA
fragment was inserted into the EcoRI and XhoI sites of the
pcDNA3.1-Myc expression vector. Human SERBP1 was
ampliﬁed from a full-length cDNA clone obtained from
Open Biosystems (Huntsville, AL) by using PCR with the
50-tttttggaattctatgcctgggcacttacaggaagg-30 and 50-tttttctcgag
attaagccagagctgggaatgcctctgg-30 oligonucleotides. The ampli-
ﬁed DNA fragment was then cloned in frame with a myc
tag into the pcDNA3.1-Myc expression vector using the same
restrictions sites as above. The expression vector encoding
the GFP-fused endoribonuclease G3BP protein (59) was a
generous gift from Dr Nancy Kedersha (Harvard Medical
School, Boston, MA). The pECFP-ER, -Golgi and -Mito
vectors were purchased from Clontech. All DNA construct
sequences were conﬁrmed by automated DNA sequencing
(StemCore Laboratories, Ottawa, ON, Canada).
Antibodies
A peptide corresponding to the last 22 C-terminal amino acids
of TDRD3,
723DGQPRRSTRPTQQFYQPPRARN
744, was
synthesized at W.M. Keck Foundation Biotechnology
Resource Laboratory (Yale University, New Heaven, CT).
Polyclonal antibodies were generated by Cedarlane Labora-
tories (Burlington, ON, Canada) using rabbits injected with
the synthetic peptide coupled to KLH. The polyclonal anti-
bodies were afﬁnity-puriﬁed over the antigenic peptide
coupled to Afﬁ-Gel 10 beads (Bio-Rad, Hercules, CA) follow-
ing manufacturer’s instructions, eluted in 100 mM Glycine pH
2.5, buffered with 1 M Tris–HCl pH 8.0, dialyzed against 1 
phosphate-buffered saline (1  PBS: 137 mM NaCl, 2.7 mM
KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.4) at 48C over-
night, and concentrated using Centricon centrifugal devices
(Millipore, Bedford, MA). The afﬁnity-puriﬁed anti-TDRD3
antibody (0.25 mg/ml) was used at a 1:100 dilution for IF
and at a 1:1000 dilution for western blot (IB) analysis.
Monoclonal antibodies against beta-actin (Sigma, St Louis,
MO) and glyceraldehyde-3-phosphate dehydrogenase
(Covance Canada Inc., Dorval, QC) were both used at a
1:3000 dilution (IB). Goat polyclonal anti-TIA-1 antibody
(C-20) and rabbit anti-ribosomal protein L28 (FL-137) anti-
body were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA) and used at 1:50 (IF) and 1:2500 (IB) dilutions,
respectively. Mouse anti-FMRP, clone 1C3 (ascites) was pur-
chased from Millipore and used at 1:50 (IF) or 1:2500 (IB)
dilutions. Human anti-GW182 (1:600 dilution, IF) and
ﬂuorophore-coupled anti-human (1:900 dilution, IF) anti-
bodies were generous gifts from Dr Ken Dimock (University
of Ottawa). Rabbit anti-Hsp72 (Hsp72) polyclonal antibody
was obtained from Stressgen (Ann Arbor, MI) and used at a
1:10 000 dilution (IB). Rabbit S6 ribosomal protein (5G10)
antibody was purchased from Cell Signaling Technology
(Danvers, MA) and used at a 1:5000 dilution (IB). The super-
natant of a murine hybridoma producing an anti-myc mono-
clonal antibody (9E10), purchased from ATCC, was used at
a 1:50 dilution (IF). Rabbit polyclonal anti-GST antibodies
were described elsewhere (17) and used at a 1:5000 dilution
(IB). Mouse monoclonal anti-Elongation Factor 1 alpha anti-
body was purchased from Upstate Biotechnology (Upstate,
NY) and used at a 1:3000 dilution (IB). Rabbit polyclonal anti-
bodies directed against the Ewing Sarcoma breakpoint region
1 protein (EWS; 1:40 000 dilution, IB; 1:900 dilution, IF),
DEAD box polypeptide 3 (DDX3; 1:1000 dilution, IB; 1:300
dilution, IF), and FUS/TLS (1:40 000 dilution, IB; 1:900
dilution, IF) were all purchased from Bethyl Laboratories
Inc. (Montgomery, TX). SYM10 and SYM11 antibodies
were described elsewhere (7,9) and were used at a 1:750
and 1:1000 dilution (IB), respectively. Fluorophore-coupled
anti-goat, -mouse and -rabbit secondary antibodies were
obtained from Jackson ImmunoResearch (West Grove, PA)
and used at a 1:100–200 dilution (IF). Horseradish
peroxidase-conjugated goat anti-mouse and goat anti-rabbit
secondary antibodies (MP Biomedicals, Solon, OH) were
used at a 1:4000 dilution.
Peptide competition assay and Immunoblotting
Fifty microgram of HeLa total protein extracts were resolved
on a 10% SDS–PAGE in triplicate, transferred to a PVDF
membrane and prepared as three identical western blot
strips. PVDF strips were blocked with 5% dry milk in PBST
(1  PBS, 0.05% Tween 20) for 1 h at room temperature,
and probed with either TDRD3 antibodies (0.25 mg/ml) or
an antibody:peptide solution, for 2 h at room temperature. Pre-
adsorbed antibody:peptide solutions were prepared by pre-
incubation of TDRD3 antibodies with a 200-fold molar
excess of the antigenic peptide (0.186 mg/ml) or an unrelated
synthetic peptide (0.113 mg/ml) in IB solution (1% dry milk in
PBST), for 16 h at 48C. Incubation with primary antibodies
was followed by three washes with PBST and probing with
secondary antibody under the same conditions. Proteins were
detected by chemiluminescence (Millipore) after three ﬁnal
washes in PBST.
Cell treatments and immunoﬂuorescence
When prepared for indirect IF microscopy, cells were grown
directly onto glass cover slips. Transfected HeLa cells were
treated 24–48 h post-transfection. Cellular stress response
was induced either by treatment with 0.5 mM sodium arsenite
for 30 min (oxidative stress; Ars), by incubation at 438C for
30 min (Heat shock; Hs) or by treatment with 1 M sorbitol
for 1 h followed by a 30-min recovery in isotonic culture
media (osmotic shock; Osm) (63). To inhibit methylases,
HeLa cells were treated for 20 h with 1 mM of the methyl-
transferase inhibitor MTA (Sigma) prepared in dimethyl
sulfoxide (DMSO). Control cells were mock-treated with
equal volume of DMSO. Untreated and treated cells were
ﬁxed with 4% paraformaldehyde for 10 min, permeabilized
with 0.5% Triton X-100 in PBS for 5 min and blocked with
0.1% BSA in PBS for 30 min prior to immunostaining. Cells
were incubated with primary antibodies diluted in 0.1%
BSA in PBS for 1 h. Cells were then washed once with
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incubated with the appropriate ﬂuorophore-annexed secondary
antibodies in 0.1% BSA in PBS, in the dark, for 1 h. All
incubations were performed at room temperature. The cells
were washed again as above, counterstained with DAPI and
mounted onto glass slides. Fluorescence was visualized with
a Z.1 AxioImager upright microscope (Carl Zeiss Canada
Ltd, Toronto, ON, Canada) and images were captured with
an AXIOCAM HRM R 2.0 CCD digital camera.
Protein puriﬁcation
GST-fusion proteins were overexpressed in Escherichia coli
BL-21 cells (Stratagene, La Jolla, CA) by induction with a
ﬁnalconcentrationof0.1 mMisopropyl-D-thiogalactopyranoside
(IPTG). Following induction, cells were spun down, resus-
pended in 10 ml of 1  PBS containing CompleteTM
protease inhibitor cocktail (Roche Applied Science) and
subsequently broken down by sonication (5 pulses of 15 s at
12 watts). Cell debris were discarded through centrifugation
for 20 min at 10 000g. GST-fusion proteins were then puriﬁed
using glutathione-agarose (Sigma). For GST pull-down exper-
iments, fusion proteins were kept on glutathione-agarose as
a 50% slurry in 1  PBS. Alternatively, GST-fusion proteins
were eluted from the beads using 60 mM glutathione in
1  PBS adjusted to pH 7.5. The puriﬁed tagged proteins
were dialyzed against 1 liter of 1  PBS at 48C overnight.
The dialysates were then concentrated using Amicon centrifu-
gal devices (Millipore). Protein concentration was measured
by using the DC protein assay reagent (Bio-Rad).
Peptide binding assay
Peptide binding assays were performed as previously
described (17). Brieﬂy, (RG)4 and (R
sDMAG)4 peptides were
biotinylated and pre-bound to streptavidin-agarose (Sigma)
to generate peptide afﬁnity columns. 0.35–1.4 mg of eluted
GST-fusion Tudor domain proteins were diluted in 300 mlo f
lysis buffer (1% Triton X-100, 20 mM Tris pH 7.4, 150 mM
NaCl and CompleteTM protease inhibitor cocktail) and
mixed with 20 ml of a 50% slurry of the respective peptide
afﬁnity column. The mixtures were incubated at 48C for
30 min with constant end-over-end mixing, and the beads
were washed twice with lysis buffer and once with 1  PBS.
Retained proteins were then resolved by SDS–PAGE and
detected using a rabbit anti-GST serum.
Pull downs and mass spectrometry
HeLa cells from 5   150 mm plates were lysed in lysis buffer
for 6 h at 48C and then centrifuged to remove cellular debris.
Cell lysates were incubated with either puriﬁed recombinant
GST (as a control), GST-TDRD3-Tdr or GST-TDRD3-Tdr
E691K proteins coupled to glutathione-agarose for 16 h at
48C. The beads were then washed twice with lysis buffer
and once with 1  PBS. The retained proteins were resolved
by SDS–PAGE and the gel, stained with Coomassie Blue.
The polypeptides speciﬁcally pulled-down by TDRD3-Tdr,
that were not pulled-down by GST alone, were excised from
the gel and sent out for mass spectrometry analysis and
identiﬁcation (WEMB Biochem Inc., Toronto, ON, Canada).
Brieﬂy, gel slices were incubated with trypsin and the result-
ing digested peptides ran through a matrix-assisted laser deso-
rption ionization-quadrupole-time of ﬂight (MALDI-Qq-TOF)
mass spectrometer coupled to a LCQ DECA XP ion trap. The
database search for peptide mass ﬁngerprint and MS/MS
sequencing data from MALDI-Qq-TOF was done using an
in-house database and the Mascot software. Sequencing data
generated from the ion trap was analyzed using the Sequest
software and a human database subset created from NCBI
non-redundant data (68).
Polysomal proﬁle analysis and protein extraction from
sucrose gradient fractions
5   10
6 HeLa cells were grown in 100-mm tissue culture
dishes, left untreated or incubated with 0.5 mM sodium
arsenite for 30 min, harvested and proceeded immediately.
Prior to analysis, the cells were resuspended in 1 ml of
polysomal buffer [20 mM Tris, pH 7.5, 150 mM NaCl,
1.25 mM MgCl2, 5 U/ml of RNAsine (Amersham Bioscience,
Piscataway, NJ), EDTA-free protease inhibitor cocktail (Com-
pleteTM, Roche) and 1 mM dithiothreitol]. Nonidet P-40 was
then added to a ﬁnal concentration of 1% and cells were
lysed for 15 min on ice. Extracts were clariﬁed by centrifu-
gation at 12 000g for 20 min at 48C. Twenty optical density
units (260 nm) of cytoplasmic extracts were loaded on each
10–60% linear sucrose gradient and further analyzed as
described elsewhere (65). Brieﬂy, following ultracentrifuga-
tion (40 000g for 4 h) of the sucrose gradients, 0.5-ml fractions
were collected using the gradient density fractionator system
(Teledyne Isco). mRNPs of each collected fraction were preci-
pitated overnight at 2208C by addition of 1 ml of cold ethanol
and centrifuged for 30 min at 14 000g. Proteins were then
resuspended in 150 ml Laemmli sample buffer.
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